These observations therefore gather attention to some of the current trials investigating the role of EGFR inhibitor in MM, as activating mutations in KRAS/NRAS/BRAF is believed to confer resistance to EGFR inhibition4, 5, 6. Here, KRAS is linked to Miyoshi myopathy.